Chester County News and Community Website
EXTON, PA — Lungpacer Medical has announced that the U.S. Food and Drug Administration (FDA) has approved an Investigational Device Exemption (IDE) for the STARI (STimulation to Activate RespIration) clinical trial. …
Lungpacer Medical Secures FDA Approval for AHRF Trial Read More
BERWYN, PA — Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) has announced its plans to explore utilizing Molecular Envelope Technology (MET) for the intranasal delivery of a mRNA COVID vaccine. This innovative direction …
Virpax Pharmaceuticals Explores Intranasal mRNA Vaccine Delivery Using MET Read More BERWYN, PA — Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) has commended Nanomerics for the successful completion of a human study utilizing its proprietary Molecular Envelope Technology (MET). The Phase I SUNLIGHT trial …
Virpax Pharmaceuticals Applauds Successful Trial of Molecular Envelope Technology Read More
CONSHOHOCKEN, PA — The GBS | CIDP Foundation International has unveiled survey data that paints a sobering picture of the physical, social, and financial challenges faced by individuals with Guillain-Barré Syndrome …
New Survey Sheds Light on Guillain-Barré Syndrome Challenges Read More
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced a significant milestone with the U.S. Food and Drug Administration (FDA), gaining alignment to advance its Phase 2/3 pivotal confirmatory trial of OCU410ST, …
FDA Greenlights Ocugen’s Breakthrough Gene Therapy Trial, Offering New Hope for Stargardt Disease Patients Read More EXTON, PA — Lungpacer Medical has unveiled promising results from its groundbreaking STIMULUS trial, a Phase 1 study conducted in collaboration with Toronto General Hospital. Presented at the 2025 Transcatheter Heart …
Lungpacer Medical Shares Promising Results from STIMULUS Trial Read More
MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) will hold a live webcast aimed at providing patients, caregivers, and families with updates on its clinical trials and future plans. The virtual …
Annovis Bio to Host Patient-Centered Webcast on Key Clinical Developments Read More BERWYN, PA — Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) has announced the successful completion of a full study on its localized pain management product, Probudur™, conducted in partnership with the U.S. Army …
Virpax Pharmaceuticals Advances Pain Management with Promising Probudur Study Results Read More
PHOENIXVILLE, PA — PleoPharma, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PP-01, the company’s lead investigational asset aimed at mitigating Cannabis …
FDA Grants Fast Track Designation to PleoPharma’s PP-01 for Cannabis Withdrawal Syndrome Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has announced the completion of dosing in the Phase 2 portion of its ArMaDa clinical trial for OCU410. This novel multifunctional modifier gene therapy …
Breakthrough Gene Therapy OCU410 Could Save Millions from Vision Loss – Phase 2 Milestone Achieved! Read More